For primary hyperlipidemia. ANDA 203480, held by Glenmark Pharms Ltd. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 203480 (Colesevelam Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on May 18, 2018, with 5 approved supplements and 0 published complete response letters.
Colesevelam hydrochloride tablets are a bile acid sequestrant indicated as an adjunct to diet and exercise to:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 18, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride625MG · tablet;oral | Colesevelam Hydrochloride | Rx |
| Apr 11, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 28, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 28, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 28, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 28, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 18, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters